logo
The Baseline
07 Jul 2022
Chart of the week: Analysts are positive on banks, NBFCs and packaged foods industries

 

 

With the new earnings season about to start, investors are trying to figure out which stocks are likely to see a good result, despite rising inflation and a volatile global economy. We checked the Trendlyne Forecaster estimates to identify the companies and industries analysts are most bullish on.

Here we first take a look at industries that have a ‘Strong Buy’ and ‘Hold’ stance from analysts. We then check revenue growth expectations within these industries for some Nifty 50 companies. 

Banks, NBFCs and packaged foods industries are among those  that the street is bullish on. Analysts have a ‘strong buy’ stance for these three industries. 

Within banks, Bajaj Finance has the highest expected revenue growth of 35.6% in Q1FY23. But on a QoQ basis, the expectation is of a muted 0.6% revenue growth. HDFC Bank and State Bank of India’s Q1FY23 expected YoY revenue growth, according to Trendlyne’s Forecaster estimates are 11.6% and 8.4%, respectively. Tata Consumer, part of the packaged foods industry, is expected to post revenue growth of 13.7% YoY, and  7.8% on a QoQ basis in Q1FY23.

If we look at the industries which have consensus stance of ‘Hold’ from analysts, these are pharmaceuticals, iron & steel/intermediate products, cement & cement products, 2/3 wheelers and marine port & services. Trendlyne Forecaster’s consensus estimates show that the street expects Adani Ports & SEZ Q1FY23 revenue to fall by 5.6% YoY, but on a QoQ basis, the street expects a near 12% rise in revenues. 

In Iron & Steel, JSW Steel is expected to post revenue growth of nearly 73% YoY in Q1FY23, indicating that it will probably continue its stellar run of revenue growth, despite recent export restrictions. On a QoQ basis, revenue growth is expected to be a more moderate 6.5%. 

In the auto industry, Eicher Motors’ Q1FY23 revenue is expected to grow by 69.2% YoY (on a low base) and 4.6% QoQ. And in pharmaceuticals, Sun Pharmaceuticals and Dr. Reddy’s Laboratories’ revenues are expected to grow 8.6% YoY and 12.8% YoY, respectively, and 11.7% QoQ and 2.1% QoQ, respectively. 

With many headwinds affecting industries across the board, let’s see if these companies meet or beat these consensus expectations in Q1FY23.

More from The Baseline
Recommended